GLP-1 Newsroom is your go-to source for breaking news, expert updates, trends, products, and real-world insights on everything related to GLP-1 medications, journeys, and diets.
Retatrutide is being called the “triple threat” of weight loss drugs—and it’s not even on the market yet. Developed by Eli Lilly, the same pharmaceutical giant behind tirzepatide (better known as Mounjaro and Zepbound), this new contender is generating buzz for its potential to help people lose more weight, faster.
